ADC Therapeutics SA
ADCT
$3.70
-$0.26-6.57%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 81.36M | 75.21M | 77.25M | 75.82M | 70.84M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 81.36M | 75.21M | 77.25M | 75.82M | 70.84M |
| Cost of Revenue | 78.59M | 87.95M | 93.29M | 87.88M | 88.33M |
| Gross Profit | 2.77M | -12.74M | -16.05M | -12.06M | -17.49M |
| SG&A Expenses | 79.93M | 79.37M | 81.03M | 83.00M | 85.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 187.45M | 196.24M | 203.25M | 199.80M | 199.97M |
| Operating Income | -106.10M | -121.03M | -126.00M | -123.99M | -129.14M |
| Income Before Tax | -141.61M | -165.84M | -168.76M | -149.67M | -157.68M |
| Income Tax Expenses | 1.02M | 1.10M | 1.19M | 168.00K | 166.00K |
| Earnings from Continuing Operations | -142.62 | -166.94 | -169.94 | -149.84 | -157.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -142.62M | -166.94M | -169.94M | -149.84M | -157.85M |
| EBIT | -106.10M | -121.03M | -126.00M | -123.99M | -129.14M |
| EBITDA | -105.39M | -119.98M | -124.62M | -122.64M | -127.80M |
| EPS Basic | -1.20 | -1.45 | -1.57 | -1.45 | -1.66 |
| Normalized Basic EPS | -0.66 | -0.82 | -0.89 | -0.90 | -1.03 |
| EPS Diluted | -1.20 | -1.45 | -1.57 | -1.45 | -1.66 |
| Normalized Diluted EPS | -0.66 | -0.82 | -0.89 | -0.90 | -1.03 |
| Average Basic Shares Outstanding | 507.69M | 462.79M | 431.17M | 413.12M | 388.47M |
| Average Diluted Shares Outstanding | 507.69M | 462.79M | 431.17M | 413.12M | 388.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |